The past year brought two significant FDA approvals that signal where prostate cancer treatment is heading: toward more precise, earlier-acting therapies that can delay disease progression while maintaining quality of life.
Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer
On June 3, 2025, the FDA approved darolutamide (Nubeqa) as a standalone oral therapy for metastatic castration-sensitive prostate cancer — a stage of the disease in which cancer has spread but still responds to testosterone-lowering therapy. The approval was based on the Phase III ARANOTE trial, a randomized, double-blind study involving 669 patients. Participants received either darolutamide or a placebo, alongside standard androgen deprivation therapy. The key finding: darolutamide significantly improved radiographic progression-free survival, meaning patients lived substantially longer without their cancer visibly worsening on imaging.
This marked the drug’s third FDA-approved indication, adding to its existing approvals for non-metastatic castration-resistant prostate cancer and for metastatic hormone-sensitive disease in combination with chemotherapy. The significance of the ARANOTE trial is that it established darolutamide’s effectiveness without requiring patients to also undergo docetaxel chemotherapy — an important option for older patients or those for whom chemotherapy’s side effects pose unacceptable risks. Darolutamide is also known for a favorable tolerability profile compared to some older agents in its class.
A Growing Role for Genomic Testing
Alongside new drug approvals, researchers are increasingly focusing on who should receive which treatment and when. At the ASCO GU and EAU 2026 conferences, new data emerged around the Decipher genomic test, which analyzes the genetic profile of a tumor to identify patients with advanced prostate cancer who may need more aggressive treatment. Separately, researchers reported that approximately 9% of patients with advanced prostate cancer carry inherited genetic mutations associated with more aggressive disease — a finding with immediate implications for genetic counseling and for selecting patients who may benefit from PARP inhibitor therapies, another class of targeted drugs now approved in this setting.
The emerging picture across all of these advances is consistent: prostate cancer care is moving away from one-size-fits-all approaches and toward a more individualized model, where imaging, genomics, and a growing toolkit of targeted therapies allow oncologists to match the right treatment to the right patient at the right time. For the estimated 1 in 8 men who will receive a prostate cancer diagnosis during their lifetime, that shift represents real and growing reason for hope.
These articles are intended for general informational purposes. Please consult a qualified healthcare provider for advice specific to your medical situation.